Cargando…
Successful use of lanadelumab in a patient with hereditary angioedema with normal C1 inhibitor and negative genetic testing
We report an approximately 80% reduction in angioedema attacks with lanadelumab, a mAb targeting plasma kallikrein, in a case of hereditary angioedema with normal C1 inhibitor levels. This finding supports a central pathophysiologic role for kallikrein in hereditary angioedema with normal C1 levels...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509950/ https://www.ncbi.nlm.nih.gov/pubmed/37780787 http://dx.doi.org/10.1016/j.jacig.2023.100087 |